Pfizer to buy maker of attention-deficit drug for $255 million

Mon Oct 22, 2012 8:44am EDT

The entrance of Pfizer World headquaters in New York City, August 31, 2003. ECONM REUTERS/Jeff Christensen JC

The entrance of Pfizer World headquaters in New York City, August 31, 2003. ECONM

Credit: Reuters/Jeff Christensen JC

Related Topics

(Reuters) - Pfizer Inc said it would buy privately held-NextWave Pharmaceuticals for $255 million, gaining access to the company's attention deficit hyperactivity disorder drug, the first once-daily liquid medicine approved to treat the condition in the United States.

NextWave's shareholders would also be eligible to get up to $425 million based on certain sales milestones.

Pfizer said it was exercising its option to acquire NextWave under an agreement signed in the second quarter, under which it had made an option payment of $20 million.

The drug, Quillivant XR, is expected to be available in pharmacies by early next year.

(Reporting by Zeba Siddiqui in Bangalore; Editing by Sreejiraj Eluvangal)

FILED UNDER: